

References

S-241

1. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Aliment Pharmacol Ther.* 2015;41:835-843.
2. Weingarden A, González A, Vázquez-Baeza Y, et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent *Clostridium difficile* infection. 2015;3:10.
3. Hayes, Inc. Health Technology Brief. *Fecal Microbiota transplant for Refractory or Recurrent Clostridium Difficile Infection in Adult.* Lansdale, PA.: Hayes, Inc.; September 2019.
4. Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P. Methods and reporting studies assessing fecal microbiota transplantation: A systematic review. *Ann Intern Med.* 2017;167(1):34-39.
5. Kao D, Roach B, Silva M, et al. Effect of oral capsule vs colonoscopy delivered fecal microbiota transplantation on recurrent *clostridium difficile* infection: A randomized clinical trial. *JAMA.* 2017;318(20):1985-1993.
6. Panchal P, Budree S, Scheeler A, et al. Scaling safe access to fecal microbiota transplantation: past, present, and future. *Curr Gastroenterol Rep.* 2018;20(4):14.
7. Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in individuals with ulcerative colitis: A randomized clinical trial. *JAMA.* 2019;321(2):156-164.
8. Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms 2019: <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse>. Accessed July 3, 2019.

9. McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Infect. Dis.* 2018;66(7).
10. Hayes, Inc. Emerging Technology Report. *SER-109 for Fecal Microbiota Transplantation*. Lansdale, PA.: Hayes, Inc.; July, 2020.
11. Hayes, Inc. Emerging Technology Report. *RBX2660 for Fecal Microbiota Transplantation*. Lansdale, PA.: Hayes, Inc.; July, 2020.
12. National Institute for Health and Care Excellence (NICE). Faecal microbiota transplant for recurrent Clostridium difficile infection. London, UK: National Institute for Health and Care Excellence; 2014. NICE Technology Appraisal Guidance No. IPG484. Available at: nice.org.uk/guidance/ipg485. Accessed September 25, 2020
13. Hayes, Inc. Evidence Analysis Research Brief. *Fecal Microbiota Transplantation for Treatment of Inflammatory Bowel Disease*. Lansdale, PA.: Hayes, Inc.; July, 2020.
14. Quraishi MN, Widlak M, Bhala NA, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. *Aliment Pharmacol Ther.* 2017;46(5):479-93.
15. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. *Jama.* 2014;312(17):1772-8.
16. Jiang ZD, Jenq RR, Ajami NJ, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial. *PLoS One.* 2018;13(11):e0205064.
17. Staley C, Hamilton MJ, Vaughn BP, et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. *Am J Gastroenterol.* 2017;112(6):940.